Tango Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
TNGX$24.30+6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEM ENTS OF CASH FLOWS
(in thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Cash flows from operating activities | |||
| Net loss | $(101,594) | $(130,302) | $(101,744) |
| Adjustments to reconcile net loss to net cash from operating activities: | |||
| Depreciation | 2,281 | 2,499 | 2,415 |
| Noncash operating lease expense | 3,961 | 3,745 | 3,606 |
| Stock-based compensation | 26,430 | 28,897 | 19,079 |
| Accretion on marketable securities | (2,688) | (4,617) | (3,394) |
| Other, net | (77) | 23 | 22 |
| Changes in operating assets and liabilities: | |||
| Accounts receivable | — | — | 2,000 |
| Prepaid expenses and other current assets | (1,763) | 370 | (2,225) |
| Other long-term assets | (299) | 43 | (41) |
| Accounts payable | (825) | (1,184) | (1,705) |
| Accrued expenses and other liabilities | 1,104 | 1,134 | (2,029) |
| Operating lease liabilities | (3,032) | (2,140) | (2,439) |
| Deferred revenue | (62,384) | (29,969) | (31,527) |
| Net cash used in operating activities | (138,886) | (131,501) | (117,982) |
| Cash flows from investing activities | |||
| Purchase of property and equipment | (1,048) | (754) | (1,526) |
| Sales and maturities of marketable securities | 224,640 | 327,768 | 353,526 |
| Purchases of marketable securities | (264,457) | (240,888) | (310,574) |
| Net cash (used in) provided by investing activities | (40,865) | 86,126 | 41,426 |
| Cash flows from financing activities | |||
| Proceeds from issuance of common stock and pre-funded warrants | 212,400 | 41,723 | 80,017 |
| Proceeds from issuance of common stock upon exercise of stock options and purchase of shares under ESPP | 10,136 | 5,941 | 1,941 |
| Return of capital from a stockholder - related party | — | — | 689 |
| Payment of transaction costs | (36) | — | (241) |
| Net cash provided by financing activities | 222,500 | 47,664 | 82,406 |
| Net change in cash, cash equivalents and restricted cash | 42,749 | 2,289 | 5,850 |
| Cash, cash equivalents and restricted cash, beginning of period | 72,097 | 69,808 | 63,958 |
| Cash, cash equivalents and restricted cash, end of period | $114,846 | $72,097 | $69,808 |
| Supplemental cash flow information: | |||
| Cash paid for leases | $5,858 | $5,603 | $5,882 |
| Supplemental disclosure of noncash investing and financing activity: | |||
| Purchases of property and equipment included in accounts payable and accrued expenses | $— | $— | $38 |
| Operating lease liabilities from obtaining right-of-use assets | $1,308 | $210 | $— |
| Revaluation of right-of-use asset and lease liability upon lease remeasurement | $1,199 | $497 | $(228) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.